Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib vs Tofacitinib in RA
NCT07008846Phase 3Active, not recruiting
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib in rheumatoid arthritis (RA), sponsored by Bangabandhu Sheikh Mujib Medical University. Started May 2025; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07008846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008846.